Eli Lilly | LLY - Pasivo Circulante





Pasivo Circulante Cambio Fecha
AbbVie USD 41.64B 458M 2026-06
Abbott USD 18.38B 1.88B 2026-03
ALKERMES USD 662.09M 62.59M 2026-06
Amgen USD 25.5B 547M 2026-06
AstraZeneca USD 31.55B 1.02B 2026-06
Baxter International USD 3.81B 218M 2026-09
Biogen USD 3.9B 18.7M 2026-09
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Coherus Biosciences USD 75.51M 56.82M 2026-06
Drreddys Laboratories INR 167.57B 165.8B 2026-03
Eli Lilly USD 47B 745M 2026-09
Gilead Sciences USD 12B 982M 2026-09
GlaxoSmithKline GBP 20.72B 814M 2026-09
Glaxosmithkline GBP 22.43B 6.39B 2026-03
J&J USD 55.46B 562M 2026-09
Medtronic USD 11.8B 141M 2026-06
Merck USD 27.73B 786M 2026-06
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novartis USD 31.75B 374M 2026-06
Novartis USD 31.37B 4.1B 2026-03
Novo Nordisk DKK 239.08B 13.92B 2026-06
Perrigo USD 1.05B 57.2M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Phibro Animal Health USD 316.47M 34.6M 2026-06
Prestige Brands USD 153.81M 32.88M 2026-06
Regeneron Pharmaceuticals USD 6.2B 671.5M 2026-09
Roche Holding CHF 28.85B 846M 2026-06
Sanofi EUR 31.93B 1.92B 2026-06
Sanofi EUR 30.01B 1.66B 2026-03
United Therapeutics USD 607.8M 8.7M 2026-06
Zoetis USD 2.06B 8M 2026-06